Previous close | 4.3700 |
Open | 4.4500 |
Bid | 4.0700 x 700 |
Ask | 4.1200 x 400 |
Day's range | 4.0700 - 4.4900 |
52-week range | 1.0400 - 5.8500 |
Volume | |
Avg. volume | 4,848,847 |
Market cap | 277.32M |
Beta (5Y monthly) | 1.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.00 |
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in patients with advanced metastatic solid tumors including melanoma, renal cell carcinoma and head and neck squamous cell carcinoma - SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeuti
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th- SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose